, Tracking Stock Market Picks
Enter Symbol:
Inovio Biomedical Corporation (INO) [hlAlert]

Hold INO

Inovio Biomedical Corporation (INO) downgraded to Hold by Aegis Capital

Posted on: Friday,  Aug 16, 2013  8:25 AM ET by Aegis Capital

Aegis Capital rated Hold Inovio Biomedical Corporation (NASDAQ: INO) on 08/16/2013. Previously Aegis Capital rated Buy Inovio
Biomedical Corporation (NASDAQ: INO) on 03/11/2013., when the stock price was $2.12. Since then, Inovio Biomedical Corporation has gained 171.70% of its value until Aegis Capital rated INO Buy on 08/16/2013, when the price was $5.76. .

Inovio Biomedical Corporation (Inovio) is a San Diego-based biomedical company focused on the development of vaccines to prevent or treat cancers and chronic infectious diseases. Inovio develops deoxyribonucleic acid (DNA) delivery solutions based on electroporation, which uses brief, controlled electrical pulses to create temporary pores in cell membranes and enable increased cellular uptake of a useful biopharmaceutical. Once the DNA vaccine enters a cell, it can then express the proteins it was encoded to produce. Inovio has multiple systems designed to create different electroporation conditions for different applications consists of two documents: a pulse generator and an applicator that is inserted into selected tissue. The Company?s subsidiaries include Genetronics, Inc., Inovio AS and Inovio Asia Pte. Ltd. In June 2009, Inovio completed its merger with VGX Pharmaceuticals.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/24/2014 12:00 AM Buy
12.98 19.00
as of 12/13/2013
1 Week   
1 Month   
3 Months   
1 YTD up  171.69 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/16/2013 8:25 AM Hold
3/11/2013 10:25 AM Buy
2.12 6.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy